Genprex shares surge 29.97% after-hours on Japan, EU patent grants for REQORSA gene therapy combinations.

Genprex surged 29.97% in after-hours trading following announcements that the Japanese and European Patent Offices granted patents for REQORSA Gene Therapy in combination with PD-L1 and PD-1 antibodies, respectively. These approvals strengthen the company’s intellectual property portfolio for its lead oncology candidate and support the Acclaim-3 clinical trial for small cell lung cancer. The patents, which expand global protection alongside existing U.S. and Korean patents, were highlighted as validation of Genprex’s therapeutic approach and reinforce its competitive positioning in gene therapy. The stock’s sharp rise aligns with positive market reaction to the expanded IP coverage and the potential for long-term commercial exclusivity in key markets.